Get the Stockscreener App
1.2024
3.81%
-0.0476
Nyxoah Sa stock is traded at $1.2024, with a volume of 90,598.
It is down -3.81% in the last 24 hours and down -21.92% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$1.25
Open:
$1.2
24h Volume:
90,598
Relative Volume:
0.89
Market Cap:
$122.45M
Revenue:
$17.85M
Net Income/Loss:
$-96.93M
P/E Ratio:
-0.4861
EPS:
-2.4735
Net Cash Flow:
$-88.29M
1W Performance:
-10.93%
1M Performance:
-21.92%
6M Performance:
-64.37%
1Y Performance:
-80.26%
1-Day Range:
$1.195
$1.22
1-Week Range:
$1.235
$1.3788
52-Week Range:
$1.195
$6.2034
Nyxoah Sa Stock (NYXH) Company Profile
Compare NYXH vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
1.2024 | 122.45M | 17.85M | -96.93M | -88.29M | -2.4735 |
ABT
Abbott Laboratories
|
104.47 | 180.77B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.28 | 121.88B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
291.70 | 111.89B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.77 | 63.43B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.59 | 49.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-26 | Downgrade | Stifel | Buy → Hold |
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains? - Zacks Investment Research
Nyxoah (NASDAQ: NYXH) Stock Price, News & Analysis - kalkine.ca
Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption? - Yahoo Finance
Nyxoah SA Actuals & Estimates (HAM:5YI) - TradingView
Gross profit of Nyxoah SA – HAM:5YI - TradingView
Price to book ratio of Nyxoah SA – HAM:5YI - TradingView
Nyxoah Begins U.S. Post-Approval Study of Genio Sleep Apnea Implant - finance.biggo.com
Cash per share of Nyxoah SA – HAM:5YI - TradingView
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial - Yahoo Finance
Nyxoah implants first patient in BREATHE study of Genio - Yahoo
Nyxoah Launches Major U.S. Post-Approval Study for Genio Sleep Apnea Device - TipRanks
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System - GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Nyxoah SA (NYXH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success - Investing.com
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success By Investing.com - Investing.com India
Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ) - Seeking Alpha
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com India
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com Canada
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com Nigeria
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com South Africa
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com Australia
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com UK
NYXH Jumps As ACCCESS Trial Data Reset The Trading Map - timothysykes.com
NYXH Stock Jumps As ACCCESS Trial De‑Risks Sleep Apnea Bet - StocksToTrade
NYXH Stock Pops As ACCCESS Trial Data Fuels Breakout Hopes - timothysykes.com
NYXH Stock Jumps As ACCCESS Trial De-Risks U.S. Growth Story - StocksToTrade
Nyxoah (ENXTBR:NYXH) Stock Forecast & Analyst Predictions - Simply Wall Street
87.7% improved on a measure of oxygen drops during sleep. No device-related serious adverse events were reported. - Stock Titan
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary - GlobeNewswire
Nyxoah SA (NYXH) Stock Price & News - Syfe
Information on the total number of voting rights and shares - GlobeNewswire
Information on the total number of voting rights and shares - Finansavisen
Nyxoah Updates Share Count and Potential Dilution From Convertible Instruments - TipRanks
Nyxoah (NYXH) Results Versus Estimates: The Available Earnings Metric Delivers a Miss in the Current Update; Market Reaction: The Share Price Sheds 2.74% in the Current UpdateEarnings Power Value - vinanet.vn
Nyxoah (NYXH) Results Versus Estimates: The Available Earnings Metric Delivers a Miss in the Current Update; Market Reaction: The Share Price Sheds 2.74% in the Current UpdateFinancial Data - dars.gov.et
Nyxoah (NYXH) Results Versus Estimates: The Available Earnings Metric Delivers a Miss in the Current Update; Market Reaction: The Share Price Sheds 2.74% in the Current UpdateRevenue Guidance Range - dars.gov.et
Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the CloseIndex Put Call - vinanet.vn
Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the CloseETF AUM Growth - siam.in
Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the CloseNarrow Range Breakout - careplusvn.com
Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the ClosePrice Gap Fill - dars.gov.et
Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com Nigeria
Cantor Fitzgerald cuts Nyxoah stock price target on valuation - Investing.com
Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com India
Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts Nyxoah stock price target on valuation - Investing.com
Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price - MarketBeat
Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com UK
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):